Data as of .
IDNA vs PBPH: which is really different?
IDNA and PBPH hold 14% of their weight in the same names.
ETFIQ Off-Index Score: IDNA scores higher
How much of it is not the index it is sold as an alternative to?
A percentile among the 379 thematic ETFs with a holdings filing. It is a position in a set, not a rating, and neither end of it is a recommendation. All thematic ETFs ranked by it · How it is computed
14% of the two portfolios are the same securities at the same weight.
What they hold in common
By the books each fund has filed, IDNA and PBPH hold 14% of their money in the same securities at the same weight.
| Holding | IDNA | PBPH |
|---|---|---|
| MERCK & CO INC | 3.57% | 4.71% |
| VERTEX PHARMACEUTICALS | 3.34% | 2.73% |
| REGENERON PHARMACEUTICALS | 3.63% | 1.72% |
| INCYTE CORP | 3.60% | 0.46% |
| EXELIXIS INC | 3.25% | 0.24% |
| Only in IDNA | Only in PBPH |
|---|---|
| MODERNA 9.54% | ELI LILLY & CO 14.74% |
| TWIST BIOSCIENCE 7.09% | JOHNSON & JOHNSON 9.10% |
| GENMAB 4.13% | ABBVIE INC 6.53% |
| BAYER AG 3.87% | ROCHE HOLDING AG-GENUSSCHEIN 5.28% |
| REVOLUTION MEDICINES 3.76% | NOVARTIS AG-REG 4.99% |
| IOVANCE BIOTHERAPEUTICS INC 3.67% | ASTRAZENECA PLC 4.60% |
| TAKEDA PHARMACEUTICAL 3.62% | NOVO NORDISK A/S-B 4.37% |
| CARIS LIFE SCIENCES 3.39% | AMGEN INC 4.33% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jan 31, 2026 and Sep 18, 2026.
Performance, window by window
| Window | Total return | vs the S&P 500 | vs the Nasdaq-100 | |||
|---|---|---|---|---|---|---|
| IDNA | PBPH | IDNA | PBPH | IDNA | PBPH | |
| 3 months | +30.3% | +12.4% | +28.1 pts | +10.1 pts | +32.8 pts | +14.8 pts |
| 6 months | +41.4% | +15.6% | +23.4 pts | −2.5 pts | +17.2 pts | −8.7 pts |
| 1 year | +73.4% | not published | +56.9 pts | not published | +51.7 pts | not published |
| 3 years | +91.3% | not published | +12.9 pts | not published | −6.9 pts | not published |
| Since launch | +69.7% | +13.3% | −123.9 pts | −0.8 pts | −242.0 pts | −5.7 pts |
| IDNA iShares Genomics Immunology and Healthcare ETF Holds 62 stocks in genomics and gene editing, 24% of its weight in S&P 500 companies | PBPH Portfolio Building Block World Pharma and Biotech Index ETF Holds 51 stocks in biotech, 57% of its weight in S&P 500 companies | |
|---|---|---|
| Issuer | iShares | Portfolio Building Block |
| Theme | Genomics and gene editing | Biotech |
| In the S&P 500 | 23.9% | 56.8% |
| Active share vs the S&P 500 | 99.1% | 95.0% |
| In the Nasdaq-100 | 7.0% | 14.7% |
| Holdings | 62 | 51 |
| Top ten, share of the fund | 46.2% | 62.7% |
| Expense ratio | 0.47% | 0.13% |
| Fee for the differing part | 0.47% | 0.14% |
| Total return, 1 year | +73.4% | +13.3% (since launch on Nov 25, 2025) |
| vs the S&P 500 | +56.9 pts | −0.8 pts |
| vs the Nasdaq-100 | +51.7 pts | −5.7 pts |
| Below its high | −24.7% | −4.8% |
| Net assets | $271m | $36m |
IDNA in plain words
By weight, 24% of IDNA's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 99%. The top ten holdings are 46% of the fund across 62 positions, as published by its issuer for Sep 18, 2026. Over the year to Sep 18, 2026 the fund returned +73.4% with distributions reinvested against +16.6% for the S&P 500, so a holder was ahead by 56.9 pts. It sits 24.7% below its all-time high of Sep 2, 2021.
PBPH in plain words
By weight, 57% of PBPH's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 95%. The top ten holdings are 63% of the fund across 51 positions, as filed for Jan 31, 2026. Since it launched on Nov 25, 2025 the fund returned +13.3% with distributions reinvested against +14.1% for the S&P 500, so a holder was behind by 0.8 pts.
Questions people ask
- Do IDNA and PBPH hold the same stocks?
- By their latest filings, 14% of their books are the same securities at the same weight, which is mostly different names. Overlap is the sum of the smaller weight of every security they share.
- Which is more different from the S&P 500, IDNA or PBPH?
- IDNA has 24% of its weight in S&P 500 names and PBPH has 57%, so IDNA differs more from the index.
- Which is cheaper, IDNA or PBPH?
- IDNA charges 0.47% a year and PBPH charges 0.13%, so PBPH is cheaper. Fees come from each fund's prospectus.
Other comparisons
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, IDNA against PBPH, data as of Sep 18, 2026. https://etfiq.com/compare/themes/idna-vs-pbph Free to use with attribution; the underlying files are at Open data.